Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Son, Seok Hyun ^a   Kay, Chul Seung ^a   Song, Jin Ho ^a   Lee, Sea Won ^a   Choi, Byung Ock ^a   Kang, Young Nam ^a   Jang, Jeong Won ^a   Yoon, Seung Kew ^a   Jang, Hong Seok ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Child Pugh score (CP score); Dosimetric parameter; Helical tomotherapy; Hepatocellular carcinoma (HCC); Radiation induced hepatic toxicity (RIHT); The deterioration of hepatic function

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; DEVICE THERAPY; DOSIMETRY; FEMALE; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; RADIATION DOSE; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TOMOTHERAPY; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PROBABILITY; RADIATION INJURIES; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; ROC CURVE; YOUNG ADULT;

EID: 84872018535     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-11     Document Type: Article

References (20)

1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56(4):918-928. 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E, 2990661.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94(2):153-156. 10.1002/ijc.1440, 11668491.
3. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224(1):47-54. 10.1148/radiol.2241011262, 12091661.
4. Lencioni R, Pinto F, Armillotta N, Bassi AM, Moretti M, Di Giulio M, Marchi S, Uliana M, Della Capanna S, Lencioni M, et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997, 7(4):514-519. 10.1007/s003300050194, 9204330.
5. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001, 221(1):159-166. 10.1148/radiol.2211001624, 11568334.
6. Cochrane AM, Murray-Lyon IM, Brinkley DM, Williams R. Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma. Cancer 1977, 40(2):609-614. 10.1002/1097-0142(197708)40:2<609::AID-CNCR2820400203>3.0.CO;2-L, 196734.
7. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995, 31(5):1237-1248. 10.1016/0360-3016(94)00418-K, 7713785.
8. Cheng JC, Chuang VP, Cheng SH, Huang AT, Lin YM, Cheng TI, Yang PS, You DL, Jian JJ, Tsai SY, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000, 47(2):435-442. 10.1016/S0360-3016(00)00462-4, 10802371.
9. Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, Yoo BC, Lee JE, Kang MK, Park YJ, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005, 61(4):1143-1150. 10.1016/j.ijrobp.2004.08.028, 15752895.
10. Robertson JM, McGinn CJ, Walker S, Marx MV, Kessler ML, Ensminger WD, Lawrence TS. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys 1997, 39(5):1087-1092. 10.1016/S0360-3016(97)00550-6, 9392548.
11. Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM, Suh CO, Kim GE. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999, 43(2):393-397. 10.1016/S0360-3016(98)00415-5, 10030267.
12. Cheng JC, Wu JK, Huang CM, Liu HS, Huang DY, Cheng SH, Tsai SY, Jian JJ, Lin YM, Cheng TI, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 2002, 54(1):156-162. 10.1016/S0360-3016(02)02915-2, 12182986.
13. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002, 53(4):810-821. 10.1016/S0360-3016(02)02846-8, 12095546.
14. Kim TH, Kim DY, Park JW, Kim SH, Choi JI, Kim HB, Lee WJ, Park SJ, Hong EK, Kim CM. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67(1):225-231. 10.1016/j.ijrobp.2006.08.015, 17056199.
15. Lee IJ, Seong J, Shim SJ, Han KH. Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. Int J Radiat Oncol Biol Phys 2009, 73(1):154-158. 10.1016/j.ijrobp.2008.04.035, 18823715.
16. Liang S, Huang X, Zhu X, Zhang W, Cai L, Huang H, Li Y, Chen L, Liu M. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh Grade A cirrhosis. Radiother Oncol 2011, 98(2):265-269. 10.1016/j.radonc.2010.10.014, 21056489.
17. Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006, 65(2):426-434. 10.1016/j.ijrobp.2005.12.031, 16690430.
18. Liaw Y, Sung JJ, Chow WC, Farrell G, Lee C, Yuen H, Tanwandee T, Tao Q, Shue K, Keene ON, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351(15):1521-1531. 10.1056/NEJMoa033364, 15470215.
19. Furuse J, Ishii H, Nagase M, Kawashima M, Ogino T, Yoshino M. Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2005, 20(10):1512-1518. 10.1111/j.1440-1746.2005.03916.x, 16174067.
20. Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, Yoon SK, Choi IB, Kang KM, Jang HS. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 2010, 78(4):1073-1080. 10.1016/j.ijrobp.2009.09.009, 20207492.